We investigated whether the ETS1–KIF14 pathway is involved downstream of activated AKT and whether downregulating KIF14 enhanced the efficacy of sorafenib in sorafenib-resistant HCC by inhibiting AKT activation. Here, KIF14 is linked to hepatocellular carcinoma.